Latest:
Useless Medical Devices
Throughout history, the public's pursuit of good health has, in the absence of scientific method or even common sense, motivated the creation of some downright ridiculous medical devices.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Christen Brown, MS
Latest:
Oncology Fellows: Reminding Ourselves of How Far We've Come
For us, a group of 15 black students at Tulane University School of Medicine (TUSCOM), a visit to the Whitney Plantation in Edgard, Louisiana, was a no-brainer. The process of navigating medical school is pure hell at times, and you need inspiration wherever and whenever you can get it.
Christian G. Downs, JD, MHA
Latest:
Christian Downs on the 34th National Oncology Conference
Christian G. Downs, JD, MHA, executive director of the Association of Community Cancer Centers (ACCC), discusses the upcoming 34th National Oncology Conference, taking place October 18 to 20 in Nashville, Tennessee.
Christian Gisselbrecht, MD
Latest:
Dr. Christian Gisselbrecht on Outcomes of Relapsed DLBCL
Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).
Christian Rolfo, MD, PhD
Christian Rolfo, MD, PhD, is the director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center—James and a professor in the College of Medicine at The Ohio State University
Latest:
FDA Approval Insights: Taletrectinib in ROS1+ Advanced/Metastatic NSCLC: With Joel Neal, MD, PhD; and Christian Rolfo, MD, PhD
Drs Neal and Rolfo discuss the significance of the FDA approval of taletrectinib for the treatment of locally advanced or metastatic, ROS1-positive NSCLC.
Christie J. Hilton, DO
Latest:
Dr Hilton on Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer
Christie J. Hilton, DO, discusses the first-line standard of care and changes in the second-line SOC, including key findings from the phase 3 DESTINY-Breast03 trial, in patients with HER2-positive metastatic breast cancer.
Christin Melton & Christina Loguidice
Latest:
Introducing the Oncology Specialty Group
Oncology & Biotech News is now united with the experienced publishing, editorial, and creative staff of Oncology Net Guide and OncLive Nursing under the Oncology Specialty Group umbrella, which also includes our newest publication, Contemporary Oncology.
Christin Melton, ELS
Latest:
Bounty of New HCC Therapies Spurs Need for More Research
The optimal integration of new drugs into the treatment paradigm of HCC requires several key developments, including greater research into biomarkers that would help inform therapy choices, earlier treatment for patients diagnosed with HCC, and clinical trials that test combination strategies.
Christina M. Annunziata, MD, PhD
Latest:
Dr. Annunziata on Efforts to Prevent Gynecologic Cancers
Christina M. Annunziata, MD, PhD, investigator, Women's Malignancies Branch, head, Translational Genomics Section, National Cancer Institute, discusses the importance on efforts being done to prevent gynecologic cancers.
Christine Bestvina, MD
Latest:
Looking Ahead in NSCLC Oncodrivers and Targeted Therapies
Panelists discuss how ASCO 2025 highlighted exciting advances in targeted therapy including neoadjuvant approaches, dynamic biomarkers like circulating tumor DNA, mixed results with HER3-directed antibody-drug conjugates (ADCs) in the EGFR space, but promising data with trastuzumab-based ADCs, emphasizing the critical importance of comprehensive biomarker testing to ensure no patients miss potentially life-changing targeted therapies.
Christine M. Duffy, MD, MPH
Latest:
Survivorship Starts at Diagnosis in Breast Cancer
The inclusion of patients from the time of diagnosis and encompassing family, friends, and caregivers is central to moving survivorship care forward, especially for breast cancer survivorship, which has high survival rates for early disease and the emergence of novel treatments for advanced cancers.